The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Gel–Liposome‐Mediated Co‐Delivery of Anticancer Membrane‐Associated Proteins and Small‐Molecule Drugs for Enhanced Therapeutic Efficacy
Abstract
A programmed drug‐delivery system that can transport different anticancer therapeutics to their distinct targets holds vast promise for cancer treatment. Herein, a core–shell‐based “nanodepot” consisting of a liposomal core and a crosslinked‐gel shell (designated Gelipo) is developed for the sequential and site‐specific delivery (SSSD) of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and doxorubicin (Dox). As a small‐molecule drug intercalating the nuclear DNA, Dox is loaded in the aqueous core of the liposome, while TRAIL, acting on the death receptor (DR) on the plasma membrane, is encapsulated in the outer shell made of crosslinked hyaluronic acid (HA). The degradation of the HA shell by HAase that is concentrated in the tumor environment results in the rapid extracellular release of TRAIL and subsequent internalization of the liposomes. The parallel activity of TRAIL and Dox show synergistic anticancer efficacy. The half‐maximal inhibitory concentration (IC 50) of TRAIL and Dox co‐loaded Gelipo (TRAIL/Dox‐Gelipo) toward human breast cancer (MDA‐MB‐231) cells is 83 ng mL–1 (Dox concentration), which presents a 5.9‐fold increase in the cytotoxicity compared to 569 ng mL–1 of Dox‐loaded Gelipo (Dox‐Gelipo). Moreover, with the programmed choreography, Gelipo significantly improves the inhibition of the tumor growth in the MDA‐MB‐231 xenograft tumor animal model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
Kluck, R. M., Bossy-Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,714
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Hyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007540200 · Cited by 1,662
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis
Lakhani, S. A., Masud, A., Kuida, K., Porter, G. A., Booth, C. J., Mehal, W. Z., Inayat, I., & Flavell, R. A. (2006) · Science · doi:10.1126/science.1115035 · Cited by 1,178
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,024
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action
Stern, R., & Jedrzejas, M. J. (2006) · Chemical Reviews · doi:10.1021/cr050247k · Cited by 804
Torchilin, V. P., Rammohan, R., Weissig, V., & Levchenko, T. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151247498 · Cited by 777
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Wang, H., Zhao, Y., Wu, Y., Hu, Y.-L., Nan, K., Nie, G., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.032 · Cited by 603
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane, M., Ettenberg, S. A., Nau, M. M., RUSSELL, E. K., & Lipkowitz, S. (1999) · PubMed · Cited by 551
Tailoring nanocarriers for intracellular protein delivery
Gu, Z., Biswas, A., Zhao, M., & Tang, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00227e · Cited by 543
Self-citationWang, C., Xu, H., Liang, C., Liu, Y., Li, Z., Yang, G., Cheng, L., Li, Y., & Liu, Z. (2013) · ACS Nano · doi:10.1021/nn4017179 · Cited by 483
Xiong, X.-B., & Lavasanifar, A. (2011) · ACS Nano · doi:10.1021/nn2013707 · Cited by 411
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., Torchilin, V. P., & Munn, L. L. (2002) · PubMed · Cited by 372
RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors
Zhen, Z., Tang, W., Chen, H., Lin, X., Todd, T., Wang, G., Cowger, T., Chen, X., & Xie, J. (2013) · ACS Nano · doi:10.1021/nn305791q · Cited by 368
Liu, Y., Du, J., Yan, M., Lau, M. Y., Hu, J., Han, H., Yang, O. O., Liang, S., Wei, W., Wang, H., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.264 · Cited by 339
Tumor necrosis factor, cancer and anticancer therapy
MOCELLIN, S., ROSSI, C., PILATI, P., & NITTI, D. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.11.001 · Cited by 311
Intercellular delivery of functional p53 by the herpesvirus protein VP22
Phelan, A., Elliott, G., & O'Hare, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0598-440 · Cited by 283
Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264
Multistage pH‐Responsive Liposomes for Mitochondrial‐Targeted Anticancer Drug Delivery
Mo, R., Sun, Q., Xue, J., Li, N., Li, W., Zhang, C., & Ping, Q. (2012) · Advanced Materials · doi:10.1002/adma.201201498 · Cited by 244
Self-citationBae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley, A. L., Liu, L. F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F. C., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 225
Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 212
Combinatorial Drug Conjugation Enables Nanoparticle Dual‐Drug Delivery
Aryal, S., Hu, C. J., & Zhang, L. (2010) · Small · doi:10.1002/smll.201000631 · Cited by 183
Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery
Khalil, I. A., Kogure, K., Futaki, S., Hama, S., Akita, H., Ueno, M., Kishida, H., Kudoh, M., Mishina, Y., Kataoka, K., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302910 · Cited by 178
Protein Nanocapsule Weaved with Enzymatically Degradable Polymeric Network
Gu, Z., Yan, M., Hu, B., Joo, K., Biswas, A., Huang, Y., Lu, Y., Wang, P., & Tang, Y. (2009) · Nano Letters · doi:10.1021/nl902935b · Cited by 144
Self-citationChen, Y., Gao, Y., Chen, H., Zeng, D., Li, Y., Zheng, Y., Li, F., Ji, X., Wang, X., Chen, F., et al. (2012) · Advanced Functional Materials · doi:10.1002/adfm.201102052 · Cited by 143
Increased hyaluronidase levels in breast tumor metastases
Bertrand, P., Girard, N., Duval, C., d'Anjou, J., Chauzy, C., Ménard, J.-F., & Delpech, B. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<327::aid-ijc4>3.0.co;2-1 · Cited by 135
Mo, R., Sun, Q., Li, N., & Zhang, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.030 · Cited by 122
Self-citationLataste, H., Sénilh, V., Wright, M., Guénard, D., & Potìer, P. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.13.4090 · Cited by 117
PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy
Chen, Z., Penet, M., Nimmagadda, S., Li, C., Banerjee, S. R., Winnard, P. T., Artemov, D., Glunde, K., Pomper, M. G., & Bhujwalla, Z. M. (2012) · ACS Nano · doi:10.1021/nn301725w · Cited by 107
Kim, E., Yang, J., Park, J., Kim, S., Kim, N. H., Yook, J. I., Suh, J., Haam, S., & Huh, Y. (2012) · ACS Nano · doi:10.1021/nn300289u · Cited by 88
Gradishar, W. J., Meza, L., Amin, B., Samid, D., Hill, T. R., Chen, Y.-M., Lower, E. E., & Marcom, P. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.128 · Cited by 87
PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy
Jiang, H. H., Kim, T. H., Lee, S., Chen, X. S., Youn, Y. S., & Lee, K. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.051 · Cited by 53
Liposomal delivery as a mechanism to enhance synergism between anticancer drugs
Lee, R. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-c02 · Cited by 20
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Lu, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.75 · Cited by 1,421
Self-citationAdvances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Enzyme-responsive nanomaterials for controlled drug delivery
Hu, Q., Katti, P. S., & Gu, Z. (2014) · Nanoscale · doi:10.1039/c4nr04249b · Cited by 668
Self-citationAnticancer Platelet‐Mimicking Nanovehicles
Hu, Q., Sun, W., Qian, C., Wang, C., Bomba, H. N., & Gu, Z. (2015) · Advanced Materials · doi:10.1002/adma.201503323 · Cited by 630
Self-citation
Metadata
- Authors
- Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2014-01-02
- Volume
- 24
- Issue
- 16
- Pages
- 2295-2304
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W2015821654
- Cited by
- 298
- References
- 50
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.